Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company, has granted inducement stock options to a new employee. The company issued 35,000 stock options with an exercise price of $7.27 per share, matching the closing price on September 8, 2025.
The options, granted under the 2022 Inducement Stock Incentive Plan, have a ten-year term with a four-year vesting schedule. The vesting includes 25% after the first year and 6.25% quarterly over the following three years, contingent on continued employment.
Fulcrum Therapeutics (Nasdaq: FULC), un'azienda biofarmaceutica in fase clinica, ha concesso stock option di indurimento a un nuovo dipendente. L'azienda ha emesso 35.000 stock option con un prezzo di esercizio di $7,27 per azione, pari al prezzo di chiusura del 8 settembre 2025.
Le opzioni, concesse nell'ambito del 2022 Inducement Stock Incentive Plan, hanno una durata di dieci anni e un calendario di vesting di quattro anni. Il vesting prevede 25% dopo il primo anno e 6,25% ogni trimestre nei tre anni successivi, soggetto al proseguimento dell'impiego.
Fulcrum Therapeutics (Nasdaq: FULC), una empresa biofarmacéutica en etapa clínica, ha otorgado opciones de acciones por motivos de contratación a un nuevo empleado. La compañía emitió 35,000 opciones con un precio de ejercicio de $7.27 por acción, equivalente al cierre del 8 de septiembre de 2025.
Las opciones, otorgadas bajo el Plan de Incentivo de Acciones por Contratación 2022, tienen un plazo de diez años con un cronograma de vesting de cuatro años. El vesting incluye 25% al primer año y 6.25% trimestralmente durante los siguientes tres años, sujeto a la continuidad en el empleo.
Fulcrum Therapeutics(나스닥: FULC)는 임상 1상 기업인 생물의약 회사로, 신규 직원에게 채용 인센티브 주식 옵션을 부여했습니다. 회사는 35,000주 옵션을 주당 $7.27의 행사가로 발행했으며 이는 2025년 9월 8일 종가와 일치합니다.
이 옵션은 2022년 채용유인 주식 인센티브 플랜에 따라 부여되었고, 10년 만기의 기간과 4년의 vesting 일정을 가집니다. 베스팅은 1년 차에 25%이고 이후 3년 동안 매 분기 6.25%씩 vest 됩니다. 이는 고용이 지속되는 경우에 한합니다.
Fulcrum Therapeutics (Nasdaq: FULC), une société biopharmaceutique en phase clinique, a accordé des options d'achat d'actions à un nouvel employé. La société a émis 35 000 options avec un prix d'exercice de 7,27 $ par action, équivalent au cours de clôture du 8 septembre 2025.
Les options, accordées dans le cadre du Plan d'incitation d'actions 2022, ont une durée de dix ans avec un calendrier d'acquisition sur quatre ans. L'acquisition prévoit 25% après la première année et 6,25% chaque trimestre sur les trois années suivantes, sous réserve du maintien de l'emploi.
Fulcrum Therapeutics (Nasdaq: FULC), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat einem neuen Mitarbeiter Incentive-Aktienoptionen gewährt. Das Unternehmen hat 35.000 Aktienoptionen mit einem Ausübungspreis von $7,27 pro Aktie ausgegeben, der dem Schlusskurs vom 8. September 2025 entspricht.
Die Optionen, gewährt im Rahmen des 2022 Inducement Stock Incentive Plan, haben eine Laufzeit von zehn Jahren und einen Vesting-Zeitplan von vier Jahren. Das Vesting sieht 25% nach dem ersten Jahr und vierteljährlich 6,25% über die folgenden drei Jahre vor, vorausgesetzt, die Beschäftigung wird fortgesetzt.
Fulcrum Therapeutics (ناسداك: FULC)، شركة أدوية حيوية في مرحلة إكلينيكية، قامت بمنح خيار أسهم تحفيزي لموظف جديد. أصدرت الشركة 35,000 خيار أسهم بسعر ممارسة $7.27 للسهم، بما يتوافق مع سعر الإغلاق في 8 سبتمبر 2025.
تمنح الخيارات بموجب خطة حافز أسهم التوظيف لعام 2022، ولها مدة عشر سنوات وجدول تقسيط لمدة أربعة أعوام. يتضمن التقسيط 25% بعد السنة الأولى و6.25% ربع سنوياً خلال السنوات الثلاث التالية، شريطة استمرار العمل.
Fulcrum Therapeutics（纳斯达克：FULC），一家处于临床阶段的生物制药公司，已向一名新员工授予诱导性股票期权。公司发行了35,000份股票期权，行权价为$7.27/股，等同于2025年9月8日的收盘价。
这些期权在2022年诱导性股票激励计划下授予，具有十年期限，并设有四年的归属表。归属包括在第一年结束时25%，在随后的三年内按季度
- None.
- None.
CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to a new employee. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement material to the new employee entering into employment with Fulcrum in accordance with Nasdaq Listing Rule 5635(c)(4).
Fulcrum granted the new employee 35,000 options to purchase shares of the company’s common stock at an exercise price of
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of SCD. Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit http://www.fulcrumtx.com and follow us on X (@FulcrumTx) and LinkedIn.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com
617-283-2856
FAQ
What stock options did Fulcrum Therapeutics (FULC) grant to its new employee?
What is the vesting schedule for FULC's newly granted stock options?
How long is the term for Fulcrum Therapeutics' newly granted stock options?
Under which plan did Fulcrum (FULC) grant these inducement stock options?
